{"id":"placebo-wo3988","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo works via the placebo effect, wherein a patient's belief in receiving treatment activates neurobiological pathways that can reduce symptoms and improve outcomes, independent of pharmacological activity. This involves activation of endogenous pain-relief systems, expectancy-driven neural responses, and conditioning mechanisms. The effect is particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue.","oneSentence":"Placebo produces therapeutic effects through patient expectation and the psychobiological response to treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:13.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03658616","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.","status":"COMPLETED","sponsor":"Dr. August Wolff GmbH & Co. KG Arzneimittel","startDate":"2018-09-18","conditions":"Primary Axillary Hyperhidrosis","enrollment":518},{"nctId":"NCT03037788","phase":"PHASE1","title":"Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis","status":"COMPLETED","sponsor":"Dr. August Wolff GmbH & Co. KG Arzneimittel","startDate":"2016-11","conditions":"Primary Axillary Hyperhidrosis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (WO3988)","genericName":"Placebo (WO3988)","companyName":"Dr. August Wolff GmbH & Co. KG Arzneimittel","companyId":"dr-august-wolff-gmbh-co-kg-arzneimittel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}